
ALT An illustrated diagram from the editorial "Science behind the Study: Optogenetics in Sight" that shows direct and indirect translational optogenetics pathways. Panel A: Precise identification of causal cells and circuits allows principled targeting, whether through direct (left), indirect neuromodulatory (middle), or indirect medicinal (right) approaches. Panel B: Components of direct optogenetics for retinitis pigmentosa are shown, including the adeno-associated virus (AAV) (top), the light-projecting goggles (middle), and the channelrhodopsin protein (bottom). The NEJM identity sits at the bottom.

ALT An illustrated diagram from the Clinical Implications of Basic Research article "The Legacy of Orexin (Hypocretin) Research in Narcolepsy and Beyond." Panel A shows the orexin system, discovered in 1998, which consists of two neuropeptides produced in the lateral hypothalamus and two G-protein–coupled receptors expressed in most areas of the brain. Panel B shows deficiency of orexin signaling leading to narcolepsy symptoms in both dogs and rodents. Panel C shows that human patients with narcolepsy lack orexin peptides in the cerebrospinal fluid (CSF), which has led to a reliable diagnostic test. Panel D shows therapeutics from 2014 to the Present.

























